A new study from Memorial Sloan Kettering Cancer Center highlights the promise of ulixertinib, a targeted therapy drug that blocks ERK, for treating certain forms of histiocytosis, including Erdheim-Chester Disease (ECD). Led by Dr. Eli Diamond, a member of the ECDGA...
One of the most valuable parts of the ECDGA Patient and Family Gathering is the opportunity for patients and caregivers to hear directly from the experts. During this year’s event in Barcelona, leading Erdheim-Chester Disease physicians participated in a live Q&A...
Dr. Eli Diamond, a leading expert in Erdheim-Chester Disease, presented at the 2025 ECDGA Patient and Family Gathering in Barcelona. His dedication to advancing research and improving care continues to make a profound impact on the ECD community. We are honored to...
